Tag Archives: Halozyme

October, 2018

30 October
Halozyme Licenses New ENHANZE Targets For $25 Million Upfront Payment, Future Milestones And Royalties

SAN DIEGO, Oct. 30, 2018 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that it has licensed its ENHANZE® drug-delivery technology to Roche for exclusive development of a new undisclosed clinical stage therapeutic target, with an option to select two additional targets within …
Share

1 June
Halozyme Identifies Plasma Biomarkers as Potential Predictors of Survival in Pancreatic Cancer

SAN DIEGO, June 1, 2018 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will present data evaluating certain biomarkers as potential predictors of survival in patients with previously untreated metastatic pancreatic ductal adenocarcinoma at the American Society of Clinical Oncology (ASCO) annual meeting, …
Share

14 September
Bristol-Myers Squibb and Halozyme Enter Collaboration and License Agreement for ENHANZE Technology

NEW YORK & SAN DIEGO–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) and Halozyme Therapeutics, Inc. (NASDAQ:HALO) today announced a global collaboration and license agreement to develop subcutaneously administered Bristol-Myers Squibb immuno-oncology medicines using Halozyme’s ENHANZE® drug-delivery technology. “We are excited to partner with Halozyme to pursue potential new approaches to how our medicines are …
Share

31 March
Halozyme’s PEGPH20 Shows No Incremental Survival Benefit in Pancreatic Cancer Study

SAN DIEGO, March 30, 2017 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced it has been informed by SWOG, an independent network of researchers that design and conduct cancer clinical trials, that the SWOG Phase 1b/2 trial evaluating PEGPH20 plus modified FOLFIRINOX chemotherapy versus modified FOLFIRINOX alone in patients …
Share

23 November
AbbVie Terminates Development Program with Halozyme

SAN DIEGO, Nov. 21, 2016 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that AbbVie has discontinued a development program using the Halozyme ENHANZE™ platform technology and the tumor necrosis factor alpha (TNF-alpha) target following completion of a phase 1 study in which the target results were not achieved. …
Share

8 June
AbbVie to Use Halozyme’s Technology in New Collaboration and Licensing Agreement

Halozyme Therapeutics Inc. has entered a potential $1.19 billion collaboration and licensing agreement with AbbVie Inc. surrounding Halozyme’s drug-delivery technology. The company announced a global collaboration and license agreement with AbbVie to develop and commercialize products combining proprietary AbbVie compounds with Halozyme’s Enhanze platform, the company’s drug delivery platform based …
Share